Improving public health through action-oriented information
Our mission is to provide timely and high-quality information needed for decision-making, planning and evaluating vaccine and prescription drug programs by:
conducting collaborative interdisciplinary research on uptake, safety and effectiveness of the vaccines and drugs used in Manitoba;
carrying out mathematical modeling and cost-effectiveness studies;
conducting disease burden and trend studies necessary for planning the introduction of new vaccines; and
performing ad hoc investigations of vaccine and drug adverse events.
The Centre at a glance
- 12 scientists, programmers and research associates
- 6 trainees
- Over 50 ongoing projects
- $7.0 million in external funding (>$48 million in collaborative projects)
- 113 peer-reviewed publications
- More than 150 peer-reviewed abstracts and presentations
In the Media
Duo inducted into Royal Society of Canada’s college
Cancer stats sound alarm bell
Preventing cancer: Research into the use of common medicines might help
Winnipeg data a factor in developing vaccine
Study: Mutations during egg step cut last year's flu vaccine effectiveness
Mutations explain poor showing of 2012 flu vaccine
Flu vaccine offered only modest protection in 2012-13: study
Quadrivalent Human Papillomavirus Vaccine Provides Poorer Protection in Women 18 and Older or with Abnormal Cytology
HPV Vaccine: The Earlier, the Better
Old drugs, new treatments
Effectiveness of the human papillomavirus vaccination program against anogenital warts in Manitoba, Canada
The human papillomavirus (HPV) is the most common sexually transmitted infection, which is responsible for virtually all-cervical cancer. Additionally, infection with HPV types 6 and 11 are responsible for 90% of anogenital warts (AGW). Our recent publication examined the effectiveness of the quadrivalent HPV vaccine (qHPV) against the development of AGW in Manitoba. Since AGW incidence peaks months after HPV infection compared to years required to develop cervical cancer the effectiveness of qHPV at reducing the incident risk of AGW provides a good proxy for the ability of vaccination to prevent HPV associated disease.
Despite yearly decreases in HIV prevalence and transmission due to increased education, condom use, and treatment the HIV epidemic in India remains the third largest in the world. Pre-exposure prophylaxis (PrEP) provides a promising new HIV intervention to reduce HIV infection rates among high-risk populations. VDEC director Dr. Salah Mahmud is collaborating on the India PrEP trial, which seeks to examine the feasibility and impact of providing PrEP along with current preventative measures to female sex workers who are at high risk of HIV infection.
We congratulate VDEC founding director Dr. Salah Mahmud on his election as a member of the Royal Society of Canada’s (RSC) College of New Scholars, Artists, and Scientists. Election to the Royal Society is the highest honor a Canadian academic can achieve! The distinction takes into account an academics contribution to society, their interdisciplinary approaches to research and novel contributions made in their field. Dr. Mahmud’s RSC citation and the 2017 cohort of newly elected members are found here. Please also see the related news article in the current edition of UM today http://news.umanitoba.ca/duo-inducted-into-rsc-college-2/.